Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors

  • Authors:
    • Nobuyuki Arima
    • Reiki Nishimura
    • Tomofumi Osako
    • Yasuhiro Okumura
    • Masahiro Nakano
    • Mamiko Fujisue
    • Yasuyuki Nishiyama
    • Yasuo Toyozumi
  • View Affiliations

  • Published online on: October 29, 2018     https://doi.org/10.3892/ol.2018.9633
  • Pages: 616-622
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gene profiling has identified at least 4 breast cancer subtypes, including Luminal A, Luminal B, HER2‑enriched and basal‑like, and immunohistochemistry is used as a guide to determine these subtypes. In the present study, patients with ER‑positive, HER2‑negative and negative nodes were classified into 4 groups according to the PgR and the Ki‑67 status and were retrospectively examined. The analysis was based on the clinicopathological findings, and includes the recurrence score (RS) and disease‑free survival (DFS) rates. Patients with invasive breast cancer (n=1866) were classified as LA (high PgR/low Ki‑67), LB‑1 (high PgR/high Ki‑67), LB‑2 (low PgR/high Ki‑67), and LB‑3 (low PgR/low Ki‑67). In addition, 41 of the cases underwent a 21‑gene expression assay. The data revealed that T1 tumors were more prevalent in the LA group and rare in the LB‑2 group. Furthermore, nuclear grade 3 and p53 overexpression was revealed to be significantly correlated with LB‑2. In terms of prognosis, LA had a significantly more favorable DFS; however, no differences were observed in the LB‑3 group. LB‑2 had a significantly worse DFS in all cases, and in the cases administered with endocrine therapy alone. Chemotherapy in combination with endocrine therapy was administered to cases with a higher risk of recurrence. In the LB‑2 group, there was no difference in the DFS rates between the cases with endocrine therapy and chemo‑endocrine therapy. These findings suggest that chemotherapy could improve the DFS in the LB‑2 group. In addition, the majority of cases with LA, LB‑3 and LB‑1 had a RS of ≤25 and the majority of the LB‑2 cases had a RS of >25. The patients with LA and LB‑3 had a favorable DFS even in the group that received endocrine therapy alone. LB‑2 was significantly correlated with a higher degree of malignancy and benefited from chemotherapy. These data suggest that the PgR and the Ki‑67 status are effective in predicting prognosis, and for deciding on the most effective treatment strategy in patients with breast cancer.
View Figures
View References

Related Articles

Journal Cover

January 2019
Volume 17 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Arima, N., Nishimura, R., Osako, T., Okumura, Y., Nakano, M., Fujisue, M. ... Toyozumi, Y. (2019). Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors. Oncology Letters, 17, 616-622. https://doi.org/10.3892/ol.2018.9633
MLA
Arima, N., Nishimura, R., Osako, T., Okumura, Y., Nakano, M., Fujisue, M., Nishiyama, Y., Toyozumi, Y."Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors". Oncology Letters 17.1 (2019): 616-622.
Chicago
Arima, N., Nishimura, R., Osako, T., Okumura, Y., Nakano, M., Fujisue, M., Nishiyama, Y., Toyozumi, Y."Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors". Oncology Letters 17, no. 1 (2019): 616-622. https://doi.org/10.3892/ol.2018.9633